Hedge Fund - DAFNA Capital Management

DAFNA Capital Management, LLC, an SEC-registered investment advisor headquartered in Los Angeles, specializes in managing long/short portfolios primarily composed of publicly traded biotechnology and medical device companies. Established in 1999, the firm has over two decades of experience in funding advancements in medicine while diligently stewarding investor wealth. DAFNA Capital Management's core objective is to preserve capital and achieve robust annualized returns over extended periods with minimal risk. Investment gains stem from the acknowledgment of the firm's duty to enhance human health through efficient capital allocation to the most promising preventive, diagnostic, and therapeutic interventions.

Dr. Nathan Fischel, founder and CEO of DAFNA Capital Management since its establishment in January 1999, has a diverse academic and professional background. Raised in Germany and educated in France, Israel, and England, Dr. Fischel pursued his medical training at the Technion School of Medicine in Israel and completed his internship at Hadassah Hospital in Jerusalem. He furthered his medical career with residencies and fellowships in Pediatrics and Pediatric Hematology and Oncology at the Children’s Hospital and the Dana-Farber Cancer Institute, Harvard Medical School in Boston, and conducted postgraduate research in Molecular Genetics at Oxford University. Formerly a Professor of Pediatrics at UCLA School of Medicine and Director of Molecular Hematology at Cedars-Sinai Medical Center, Dr. Fischel continues to contribute as Professor Emeritus at UCLA. With a prolific research career, he has authored over 120 peer-reviewed scientific and medical publications and served as principal investigator for numerous National Institutes of Health (NIH) funded research grants. His expertise is recognized through his participation on internal and external review panels at the NIH and his appointment by the U.S. Secretary of Health and Human Services to the Advisory Council of an NIH institute. In 1993, Dr. Fischel co-founded a genomics biotechnology company, where he held the positions of Chief Scientific Officer and member of the Board of Directors until its acquisition by Warner-Lambert (Pfizer). Currently, Dr. Fischel serves on the Board of Directors of Stereotaxis Inc., a publicly traded medical technology company.

Dafna Capital Management manages assets for four clients, totaling $647,896,107 as of their Form ADV dated March 27, 2024. Their latest 13F filing for Q4 2023 disclosed $417,341,689 in managed 13F securities, with a top 10 holdings concentration of 49.63%. The fund's primary holding is SPDR Biotech ETF, with 484,000 shares held.